Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer

NCT01836653 is registered in ClinicalTrials.gov with EPS Corporation as lead sponsor.

NCT NCT01836653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer
Lead sponsor
EPS Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
March 31, 2017
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver only metastasis from kras exon 2 wild type (under protocol 1.0-1.2 edition) and ras wild type (under protocol 2.0 edition) colorectal cancer